TERAPIA
20 articole · RSS
Terapia Cluj Hits RON1.5B Turnover Threshold in 2025
Terapia Cluj, the largest local drug producer by volumes and the second largest by financial results, ended 2025 with RON1.5 billion turnover, after an increase of around 11% from 2024.
Terapia Has EUR25M Investments Earmarked for Cluj Plant
Dragos Damian, CEO of Terapia Cluj, announced in an interview with ZF the company has over EUR10 million worth of investments underway in new manufacturing technologies, expansion of end pro...
Terapia Has EUR3M Budget for Cluj Warehouse Expansion
Terapia Cluj, a local pharmaceutical producer held by India’s Sun Pharma, wants to expand its warehousing area and has a EUR3 million budget to this end.
Terapia Cluj Targets RON1B Turnover in Financial Year 2022/2023, Up 15% YOY
Dragos Damian, CEO of Terapia Cluj, wants to drive the pharmaceuticals producer to RON1 billion turnover in financial year 2022-2023, meaning an over 15% increase vs the previous financial y...
Terapia, Farmec Team Up to Produce Hand Sanitizer
Romanian cosmetics manufacturer Farmec Cluj will make its packaging lines available to medicine producer Terapia Cluj for the manufacturing of hand sanitizer.
Terapia Cluj Posts RON736M Revenue in 2019
Terapia Cluj, the largest pharmaceutical manufacturer in Romania, ended 2019 with RON736 million revenue, slightly higher than in 2018, Finance Ministry data show.
Terapia Revenue Up To RON671M In 2017
Pharmaceutical manufacturer Terapia based in Cluj, part of India’s Sun Pharma group, posted 671 million lei (EUR145 million) revenue in 2017, 18% higher than in 2016 and had 867 employees.
Terapia Cluj Net Profit Up 45% To RON143M In 2016
Pharmaceutical manufacturer Terapia based in Cluj, part of India’s Sun Pharma group, posted almost 143 million lei (EUR31 million) net profit last year, an increase of 45% on 2015, according...
Terapia Cluj: OTC Drugs Now Account For 50% Of Our Portfolio
Pharmaceutical drug manufacturer Terapia Cluj, a member of the Indian pharmaceutical group Sun Pharma, has boosted share of over-the-counter drugs to 50% of its product portfolio, double as...